BIOMARIN PHARMACEUTICAL INC (BMRN)       112.2  -0.64 (-0.57%)

112.2  -0.64 (-0.57%)

US09061G1013 - Common Stock - After market: 112.2 0 (0%)

BIOMARIN PHARMACEUTICAL INC112.2

NASDAQ:BMRN (2/3/2023, 3:30:02 PM)-0.64 (-0.57%)

After market: 112.2 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 10-26 2022-10-26/amc Earnings (Next) 02-21 2023-02-21
Ins Owners 0.55% Inst Owners 98.33%
Market Cap 20.85B Shares 185.85M
PE N/A Fwd PE 76.54
Dividend Yield N/A Analysts 84.29
IPO 07-23 1999-07-23

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BMRN Daily chart

Company Profile

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in Novato, California and currently employs 3,045 full-time employees. The firm's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.

Company Info

BIOMARIN PHARMACEUTICAL INC

105 Digital Dr

Novato CALIFORNIA 94901

P: 14155066700.0

CEO: Jean-Jacques Bienaime

Employees: 3045

Website: https://www.biomarin.com/

BMRN News

News Image9 days ago - Market News VideoBioMarin Pharmaceutical Larger Than S&P 500 Component Regions FinancialNews Image11 days ago - InvestorPlace3 Drug Stocks With Promising Pipelines for 2023

These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.

News Image23 days ago - Investor's Business DailyVertex Pharmaceuticals Stock Sees Rising Relative Strength

A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?

News Image24 days ago - The Motley Fool2 Top Biotech Stocks Defying the Bear Market

Some stocks are hitting new highs.

News Imagea month ago - BloombergBioMarin’s Gene Therapy Cuts Annual Bleeds by 80% Over 3 Years

BioMarin Pharmaceutical Inc.’s gene therapy Roctavian reduced the annualized rate of bleeding in patients with hemophilia A by 80% in a three-year study.

News Imagea month ago - BioMarin Pharmaceutical Inc.BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at 3-Year Analysis

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...

BMRN Twits

Here you can normally see the latest stock twits on BMRN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example